Please, take a look at TCTMD website, this is the entire coverage of the Matrix presentation:
This is MATRIX time @ EuroPCR 2016.
I had the privilege of presenting one of the most important subsidies of the Matrix trial, PI Marco Valgimigli, assessing the role of transradial vs. transfemoral PCI either in STEMI or NSTE-ACS patients undergoing invasive management.
Results were consistent with the main publication in Lancet last year, showing a significant benefit in terms of NACE and a strong trend in terms of improvement of MACE for the transradial approach.
This is the official TCTMD report on the late-breaking clinical trial session on BVS at the latest EuroPCR.
I am proud of being part of it, presenting the short-term data of the RAI registry. And I am also proud that our centre was the second top enroller centre in both the RAI and IT-DISAPPEARS registry!